PET/MR in recurrent glioblastoma patients treated with regorafenib: [<sup>18</sup>F]FET and DWI-ADC for response assessment and survival prediction.

Br J Radiol · 2022 · PMC8722234 · PMID 34762492

Europe PMC DOI

hedged sentence

0.5300

closest p · 10.6× alpha

0.5300

boldest claim

The sentences

failed to reach statistical significancep = 0.53not close (p > 0.1)

Similarly, the average absolute and percentage increases in ADC pathological volume were also higher in PD than SD subjects (501 mm 3 and 554% vs 33 mm 3 and 297%), and also failed to reach statistical significance ( p = 0.53).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.